



The IDMP Ontology

Collaborative Implementation of
the IDMP Standards in Pharma

The Problem:

Diverging IDMP implementations create more silos and are a risk for envisioned standardization benefits of IDMP for drug safety, innovation and operational efficiency.




ISO IDMP Standards




Silos and many costly point-to-point integrations

The IDMP Ontology provides a universal implementation of the IDMP product data model as a common language to effectively bridge the gap between people, processes, and systems.




ISO IDMP Standards




Collaborative implementation creates interoperability by design

Why an Ontology for IDMP?

- 1 Provide a digital, machine-processable standard
PDF is not enough as different groups implement it differently
- 2 Solve ambiguities of the ISO IDMP standards
and feed improvements back to ISO through systematics reviews
- 3 Bridge different views with ONE product data model
between pharma internal departments and between industry groups
- 4 Provide a vendor-agnostic, and open-source model
The ontology is fully standards-based without any proprietary aspects
- 5 Reduce implementation effort through a common core
A pharma company only needs to augment the model for internal specifics




Collaborative implementation creates interoperability by design














Alignment across the pharma value chain

Our agile governance framework ensures effective industry alignment.



How do the pharma companies plan to use the IDMP Ontology?

Company	Representative	Planned Use of the IDMP Ontology
 BAYER	Sheila Elz	Product Data Model Backbone and cross-functional integration (Regulatory, Product Supply)
 NOVARTIS	Raphael Sergent	Explore how data-centric Regulatory Information Management based on IDMP-O and a cross-functional digital product structure can reduce time-to-market for original submissions.
 GSK	Jean-Gonzague Fontaine	Creation of an IDMP Ontology aligned Knowledge Graph to bridge PLM with Manufacturing
 Roche	Quentin Darasse	<i>Planning still ongoing</i>
 MERCK	Petra Kristic	Enhancement of the Merck Substance Ontology and integration into a broader R&D ontology.
 Boehringer Ingelheim	Boris Klockow	Broaden an MDM approach established with SAP for materials to further IDMP data domains
 Johnson & Johnson	Gang Xue	Establish a common Product Data Model backbone to connect Discovery, CMC, and Commercial Scientific data to enable digital twins and automation of dossier authoring.
 AstraZeneca	Sridevi Nagarajan	Part of our Product Data Model backbone, supporting cross-functional integration and as a FAIR Data Product that supports AI/Analytics.
 AMGEN	Gerd Kleemann	The IDMP ontology is used as the first instant of a data-centric approach to a product data lifecycle that produces a federated Product Record comprised of a connected data fabric that will eliminate the manual quality control burden, give us interoperability of data enabling increased process automation and unlock the potential for new product insights and innovation (IP)
 abbvie	Rainer Winnenburg	<i>Planning still ongoing</i>
 Pfizer	April Marshall	Plan to Use the project as an opportunity to get our data to work more smartly across our internal functions


IDMP Knowledge Graph: IDMP Ontology + IDMP Data Graph

Testing the ontology along concrete use cases and data

IDMP Ontology

Formal semantic definition of concepts, relationships and attributes from the ISO IDMP standards.


- A few hundred concepts
- Need accurate and agreed patterns



IDMP Data Graph

Any data object that are described by the concepts of the IDMP Ontology

- Many millions of objects
- Our test data



Enable business users to answer questions

- What substances have a common active moiety?
- Which products contain titanium dioxide?

YOUR USE CASE



Benefits for Pharma Sponsors

- 1. Reduce risk and effort of your IDMP implementation through collaboration with other pharma companies** maximizes learning, distributes development efforts and speeds up IDMP adoption internally
- 2. Participate in close alignment with regulatory authorities and standards development organizations**
- 3. Ensure that your use cases, data challenges and technical/functional implementation requirements are addressed**
- 4. Includes support for your internal adoption by project consultants** and fast onboarding for Phase 2 joiners



Marketing & Communication

The IDMP Ontology is positioned and recognized within important communities and initiatives.

- ✓ Bi-monthly public Community of Interest webinars
- ✓ Quarterly CTADHL Transatlantic workshops
- ✓ Regular exchange with authorities from FDA, EMA, WHO
- ✓ Regular updates at e.g., IRISS, IDMP industry round table
- ✓ Presentation at various conferences including DIA Global RSIDM Forum, OMG etc.

CTADHL = Call To Action-Delivering Health Literacy; OMG = Object Management Group; DIA = Drug Information Association

Our Financial Strategy

Short-term (Phase 2: Nov 2022 – Dec 2023)

1. Increase the number of companies involved, from 7 to 12 in Q1, to 14 during 2023.
Approx. \$120k expected by each pharma company for Phase 2 in 2023
2. Take a milestone-based scoping approach to allow flexibility in scope and investment per quarter

Long-term development and maintenance strategy

- Seek additional funding sources like IHI — Gravitare Health, WP5, UNICOM
- Elevate IDMP-O methodology into an ISO Technical Specification (ISO TS)

Our Executive Advisory Board



Christian Baber / J&J
Head of Scientific & Pharmaceutical
Data, Informatics & Systems



Walid Mehanna / Merck KGaA
Group Data Officer, Senior Vice President



Michel Rider / GSK
VP & Head, Digital, Data and
Analytics Transformation



David Yee / Novartis
Global Head, NIBR Portfolio Systems at
Novartis Institutes for BioMedical Research



Benjamin Slade / Novartis
Enterprise Data Management



Thomas Seck / Boehringer
Head of Global Regulatory Affairs



Vada Perkins / Bayer
Executive Director, Regulatory Policy &
Innovation, Head of Research & Policy-Regions



Saskia Schmidt-Riddle / Bayer
Head R&D Data Assets



Vanni Carapetian / Roche
Regulatory Capability Lead



Janet Cheetham / Amgen
Executive Director, Analytical Research
and Development



Frits Stulp / CTADHL
Chairman of CTADHL Board



Victoria Gamerman / Boehringer
Global Head of Data Governance & Insights

& Project Leadership



Gerhard Noelken / Pistoia Alliance
IDMP Ontology Project Lead



Sheila Elz / Bayer
IDMP Ontology Project Champion
Master Data Manager



Jean-Gonzague Fontaine / GSK
IDMP Ontology Project Champion
Product and Substance Master Data Lead



Heiner Oberkampff / Accurids
IDMP Ontology Project Co-Lead
CEO and Co-Founder



Jan Kroh / EDM Council
IDMP Ontology Project Co-Lead
Director Open Knowledge Graph Lab



Ivana Miljkovic / OSTHUS
IDMP Ontology Project Co-Lead
Senior Consultant, Project & Team Lead

*Join us and
get involved*



Learn More

www.pistoiaalliance.org



Contact Us

ProjectInquiries@PistoiaAlliance.org



Join the Initiative

The IDMP Ontology

Pistoia
Alliance

